Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, March 18th.

Can-Fite BioPharma Price Performance

Shares of NYSE CANF opened at $1.57 on Friday. The company has a market cap of $5.56 million, a price-to-earnings ratio of -0.88 and a beta of 1.12. The stock’s 50-day moving average is $1.59 and its two-hundred day moving average is $1.86. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers increased its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.